Paul Loubet1, Solen Kernéis2, Matthieu Groh3, Pierre Loulergue4, Philippe Blanche5, Pierre Verger6, Odile Launay7. 1. Inserm, CIC 1417, Paris, France; Assistance Publique-Hôpitaux de Paris (AP-HP), Fédération d'infectiologie, Hôpital Cochin, Paris, France. 2. Inserm, CIC 1417, Paris, France; Assistance Publique-Hôpitaux de Paris (AP-HP), Fédération d'infectiologie, Hôpital Cochin, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Paris, France; Inserm, F-CRIN, Innovative Clinical Research Network in Vaccinology (I-REIVAC), Paris, France. 3. Assistance Publique-Hôpitaux de Paris (AP-HP), Fédération d'infectiologie, Hôpital Cochin, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Paris, France. 4. Inserm, CIC 1417, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Paris, France; Inserm, F-CRIN, Innovative Clinical Research Network in Vaccinology (I-REIVAC), Paris, France. 5. Assistance Publique-Hôpitaux de Paris (AP-HP), Fédération d'infectiologie, Hôpital Cochin, Paris, France. 6. Inserm, F-CRIN, Innovative Clinical Research Network in Vaccinology (I-REIVAC), Paris, France; UMR Inserm 912, SESSTIM-AMU-IRD, Marseille, France; South-eastern Health Regional Observatory (ORS Paca), Marseille, France. 7. Inserm, CIC 1417, Paris, France; Assistance Publique-Hôpitaux de Paris (AP-HP), Fédération d'infectiologie, Hôpital Cochin, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Paris, France; Inserm, F-CRIN, Innovative Clinical Research Network in Vaccinology (I-REIVAC), Paris, France. Electronic address: odile.launay@cch.aphp.fr.
Abstract
BACKGROUND: Immunocompromised patients are at increased risk for severe influenza and invasive pneumococcal diseases. Population-specific vaccine recommendations are thus warranted. This study aimed to estimate the prevalence and predictors of influenza and pneumococcal vaccine uptake in a large cohort of patients with secondary immune deficiency. METHODS: An anonymous online survey was submitted to the members of 11 French associations of immunocompromised patients. The questionnaire included questions concerning underlying disease, care and treatment, flu and pneumococcal vaccine uptake, attitudes and knowledge about vaccination. Factors associated with vaccine uptake were assessed by multivariate logistic regression. RESULTS: Among the 10,897 solicited patients, 3653 agreed to participate (33.5%): 75% were female, 20% aged 65+, 79% were followed for an autoimmune disease, 13% were solid organ recipients or waiting for transplantation and 8% were treated for hematological malignancies. 3109 (85%) participants were treated with immunosuppressive therapy. Self-reported vaccine uptake was 59% (95%CI [57-60]) against seasonal influenza and 49% (95%CI [47-50]) against pneumococcal diseases. Better knowledge of and favorable attitudes toward vaccination were positively associated with vaccine uptake while being treated with a biological therapy was negatively associated. CONCLUSION: Despite specific recommendations regarding immunocompromised patients, influenza and pneumococcal vaccination rates do not reach recommended levels. Targeted information campaigns on vaccination toward these populations should be implemented to improve vaccine coverage and thus reduce the burden of infections.
BACKGROUND: Immunocompromised patients are at increased risk for severe influenza and invasive pneumococcal diseases. Population-specific vaccine recommendations are thus warranted. This study aimed to estimate the prevalence and predictors of influenza and pneumococcal vaccine uptake in a large cohort of patients with secondary immune deficiency. METHODS: An anonymous online survey was submitted to the members of 11 French associations of immunocompromised patients. The questionnaire included questions concerning underlying disease, care and treatment, flu and pneumococcal vaccine uptake, attitudes and knowledge about vaccination. Factors associated with vaccine uptake were assessed by multivariate logistic regression. RESULTS: Among the 10,897 solicited patients, 3653 agreed to participate (33.5%): 75% were female, 20% aged 65+, 79% were followed for an autoimmune disease, 13% were solid organ recipients or waiting for transplantation and 8% were treated for hematological malignancies. 3109 (85%) participants were treated with immunosuppressive therapy. Self-reported vaccine uptake was 59% (95%CI [57-60]) against seasonal influenza and 49% (95%CI [47-50]) against pneumococcal diseases. Better knowledge of and favorable attitudes toward vaccination were positively associated with vaccine uptake while being treated with a biological therapy was negatively associated. CONCLUSION: Despite specific recommendations regarding immunocompromised patients, influenza and pneumococcal vaccination rates do not reach recommended levels. Targeted information campaigns on vaccination toward these populations should be implemented to improve vaccine coverage and thus reduce the burden of infections.
Authors: Amani S Alqahtani; Daniah M Bondagji; Abdullah A Alshehari; Mada H Basyouni; Tariq M Alhawassi; Nasser F BinDhim; Harunor Rashid Journal: World J Clin Cases Date: 2017-06-16 Impact factor: 1.337
Authors: Paul D E Miller; Alice S Forster; Thushan I de Silva; Hayley Leonard; Chloe Anthias; Michaela Mayhew; Matthias Klammer; Susan Paskar; Erin Hurst; Karl Peggs; Alejandro Madrigal; John A Snowden Journal: BMJ Open Date: 2018-08-08 Impact factor: 2.692